Active Comparator: Usual Care: Insulin delivery with either MDI, a pump without automation, or an AID system and CGM
The Usual Care group will continue to receive insulin as they did before the study. This could be by injections or by using an insulin pump with or without automation for the 17 weeks of the RCT Phase. Participants will continue to use their personal CGM as they did before the study. The Usual Care group will then use Afrezza and insulin degludec for 13 weeks in the Extension Phase. Dexcom CGM will be provided during the Extension Phase.
Biological: Rapid-acting Insulin Analog
Pharmaceutical form: clear and colorless solution for injection Route of administration: subcutaneous
Other Name: any FDA approved Rapid-acting Insulin Analog
Biological: Basal Insulin
Pharmaceutical form: clear and colorless solution for injection Route of administration: subcutaneous
Other Name: any FDA approved Basal Insulin
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
